Introduction
In January 2026, South Korea’s Ministry of Food and Drug Safety (MFDS) approved a total of 45 new investigational drug (IND) applications, signaling a strong and stable start to the year for Korea’s clinical trial environment. Matching the elevated level recorded in December 2025, January’s approvals demonstrate that Korea’s regulatory capacity and sponsor demand remain robust rather than seasonal.
The approved trials span early first-in-human studies to late-stage global Phase 3 programs, with particularly strong activity in oncology, immunology, and chronic disease areas. Both domestic Korean developers and multinational sponsors continued to actively utilize Korea as a strategic clinical trial hub. Below, we break down the key statistics from January 2026 MFDS IND approvals and discuss what these patterns reveal about Korea’s evolving role in global drug development.
January 2026 Clinical Trial Approval Highlights
- Total IND approvals: 45 drug-related clinical trials
- Domestic vs. global development:
- Domestic development: 16 trials (36%)
- Global development: 29 trials (64%)
- Trial phase distribution:
- Phase 3: 21 trials (largest share)
- Phase 1: 7 trials
- Phase 2: 7 trials
- Combined / adaptive phases (Phase 1/2, 1/2a, 2a, 2b, 2/3): 10 trials
- Leading therapeutic area:
- Oncology-related trials accounted for approximately 17 approvals (~38%), followed by metabolic, immunology, CNS, infectious disease, and rare disease programs
- Data access:
- The full January 2026 MFDS IND approval dataset is available for download on our website
IND Approvals by Development Origin: Domestic vs. Global
January 2026 continued the structural pattern observed throughout 2025: globally developed drug candidates dominated MFDS IND approvals. Of the 45 approvals, 29 trials (64%) were for internationally developed products, while 16 trials (36%) originated from domestic Korean development programs.
This sustained imbalance highlights Korea’s entrenched position as a preferred execution site for multinational clinical trials, particularly for Phase 2 and Phase 3 programs requiring rapid enrollment, regulatory predictability, and high-quality data generation. Global sponsors continue to leverage Korea’s dense hospital networks, experienced investigators, and MFDS’s efficient review timelines to support pivotal trials.
At the same time, the 16 domestically developed INDs approved in January indicate a healthy and active local innovation pipeline. Korean pharmaceutical companies, biotech firms, and academic hospitals are steadily advancing new compounds into clinical testing—primarily in early phases—reinforcing Korea’s role not only as a trial destination, but also as a source of novel drug candidates.
Strategically, this dual structure remains clear:
- Global sponsors rely on Korea for late-stage and confirmatory trials
- Domestic developers focus on early clinical validation, building assets for future global expansion or partnering
IND Approvals by Trial Phase
January’s IND approvals show a clear concentration in late-stage development, with Phase 3 trials representing the single largest category.
- Phase 3 trials (21 approvals):
These approvals were largely driven by global pharmaceutical companies conducting large, multinational confirmatory studies—particularly in oncology, metabolic disease, immunology, and rare diseases. Korea’s continued inclusion in Phase 3 programs underscores sponsor confidence in Korean data being suitable for FDA, EMA, and global regulatory submissions. - Phase 1 trials (7 approvals):
Early-phase trials remained an important component of January’s activity, with many originating from domestic sponsors. These include first-in-human safety studies, dose-escalation trials, and pharmacokinetic evaluations, reflecting Korea’s growing strength in early clinical execution. - Phase 2 and adaptive designs (17 approvals combined):
A notable portion of INDs involved combined or adaptive phase designs (Phase 1/2, 1/2a, 2a, 2b, 2/3). This trend reflects modern development strategies aimed at accelerating timelines and reducing development risk—an approach increasingly adopted by both global and Korean sponsors.
Overall, the January phase distribution reinforces Korea’s position as a full-spectrum clinical trial environment, capable of supporting programs from first-in-human through pivotal registration studies.
Therapeutic Area Breakdown
Oncology remained the dominant therapeutic area in January 2026, accounting for approximately 17 of the 45 approved trials (~38%). These oncology INDs spanned a wide range of cancer types, including solid tumors and hematologic malignancies, and featured advanced modalities such as:
- Targeted small molecules
- Immuno-oncology combinations
- CAR-T and cell-based therapies
- Novel antibody and bispecific platforms
Beyond oncology, January approvals reflected broad therapeutic diversification:
- Metabolic and cardiovascular diseases, including diabetes-related programs
- CNS and psychiatry, such as major depressive disorder
- Immunology and inflammatory diseases, including atopic dermatitis and pulmonary hypertension
- Infectious disease and vaccines, sustaining post-pandemic development momentum
- Rare diseases, highlighting Korea’s participation in global niche indications with high unmet medical need
This diversity confirms that Korea is no longer concentrated in a narrow set of indications, but instead supports a balanced and globally relevant clinical trial portfolio.
Strategic Insights: What January 2026 Signals
Several strategic conclusions emerge from January’s MFDS IND data:
- Global sponsors remain deeply committed to Korea
The sustained dominance of globally developed drugs (64%)—particularly in Phase 3—confirms Korea’s role as a core component of multinational development strategies rather than a peripheral market. - Domestic innovation continues to mature
Korean developers are consistently advancing new compounds into early clinical stages, building a foundation for future out-licensing, co-development, or global expansion. - MFDS regulatory throughput remains strong
Approving 45 drug-related INDs in a single month demonstrates MFDS’s capacity to handle high application volumes without bottlenecks—an important signal for sponsors planning multi-study portfolios. - Adaptive trial designs are becoming mainstream
The high share of combined-phase INDs suggests sponsors are increasingly prioritizing speed, flexibility, and data efficiency—areas where Korea’s clinical infrastructure offers a competitive advantage.
Conclusion
January 2026’s MFDS IND approvals confirm that Korea has entered the year with sustained clinical trial momentum, not a post-year-end slowdown. With strong global participation, a heavy concentration of Phase 3 trials, and continued domestic innovation, Korea’s clinical trial ecosystem remains both resilient and strategically important.
For global pharmaceutical companies, Korea continues to offer speed, quality, and regulatory reliability for late-stage development. For Korean biotechs and academic innovators, the environment supports early clinical advancement and global integration. Together, these forces position Korea to remain a key global clinical trial hub throughout 2026 and beyond.
Planning a clinical trial in Korea? Contact us for tailored regulatory and clinical trial support, or subscribe to our newsletter for monthly MFDS IND insights and data-driven analysis.